Establishes the "End Organ Harvesting Act of 2026"
Summary
HB3106 would add a new section to Missouri insurance law, chapter 376, titled the "End Organ Harvesting Act of 2026." The bill directs health carriers and health benefit plans to exclude coverage for human organ transplants and related post-transplant care in two situations: when the transplant is performed in the People's Republic of China, or when the organ was procured by sale or donation originating in China. The bill defines "health benefit plan" and "health carrier" broadly to include MO HealthNet, the state children's health insurance program, and Medicaid managed care organizations.
In practical terms, the measure would create a new coverage restriction within Missouri-regulated insurance products and public health coverage programs included in the bill's definitions. It does not regulate the transplant procedure itself, but instead bars insurance reimbursement for the specified transplant-related services, which could affect patients seeking organ transplants abroad or involving organs linked to China. The bill would be codified in chapter 376, RSMo, as section 376.1593 if enacted.
Impact
HB3106 would amend Missouri insurance statutes by creating section 376.1593 and imposing a new exclusion on coverage for certain organ transplants and post-transplant care. The affected entities would include private health carriers, health benefit plans, MO HealthNet, CHIP, and Medicaid managed care organizations as defined in the bill. The practical effect would be to prohibit state-regulated coverage for transplants performed in China or for organs procured through sale or donation originating in China, potentially limiting reimbursement for affected patients and providers.
Sentiment
There is limited recorded legislative sentiment available because there are no committee transcripts or votes included with the bill history. Based on the bill text and caption, the measure appears to be framed as an anti-organ-trafficking or human rights-related insurance restriction, suggesting a policy rationale focused on preventing support for organ procurement practices in China. The bill was referred to the Emerging Issues committee, but no further public discussion or voting record is provided here.
Contention
The main point of contention likely concerns the breadth and enforceability of the coverage ban, especially the inclusion of organs "procured by sale or donation originating in the People's Republic of China," which may raise questions about tracing organ origin and verifying procurement circumstances. Another potential issue is the impact on patients who may seek medically necessary transplants abroad or through international networks, as well as whether the exclusion should apply to public programs like MO HealthNet and CHIP. Because no committee debate or votes are available, specific supporters or opponents are not identified in the record provided.